Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Financial Information Operating Segment (Details)

v3.25.2
Schedule of Financial Information Operating Segment (Details) - USD ($)
12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]    
Consultants and other research and development $ 4,299,941 $ 3,548,937
Stock-based compensation expense 1,446,824 758,884
Interest expense 382,014 151,230
Interest income (257,913) (249,022)
Grant income 864,014
Other (1,195) 9,260
 Net loss (8,484,763) (8,201,703)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Pre-clinical and clinical studies 1,842,209 1,668,780
Contract manufacturing 1,196,728 795,134
Consultants and other research and development 1,261,004 1,085,023
Compensation and related benefits 1,403,200 1,733,032
Professional and consultant fees 1,291,557 1,526,442
Directors’ and officers’ insurance 497,748 469,855
Facilities, fees and other related costs 284,211 271,605
Interest expense 382,014 151,230
Interest income (257,913) (249,022)
Grant income (864,014)
Other 1,195 (9,260)
 Net loss $ (8,484,763) $ (8,201,703)